These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 30768824)

  • 21. Direct healthcare costs and clinical outcomes after insulin initiation in patients with type 2 diabetes mellitus in Spain: 24-month follow-up data from the INSTIGATE study.
    Dilla T; Nicolay C; Alvarez M; Reviriego J; Goday A; Castell C
    Endocrinol Nutr; 2013 May; 60(5):224-34. PubMed ID: 23528647
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Direct medical costs for type 2 diabetes mellitus complications in the US commercial payer setting: a resource for economic research.
    Pelletier EM; Smith PJ; Boye KS; Misurski DA; Tunis SL; Minshall ME
    Appl Health Econ Health Policy; 2008; 6(2-3):103-12. PubMed ID: 19231904
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Weight-neutral effect of once-daily insulin detemir in Chinese type 2 diabetes patients: subgroup analysis of the SOLVE study.
    Pan C; Han P; Ji L; Ji Q; Lu J; Lin J; Liu J; Su B; Shi J; Wang P
    J Diabetes; 2015 Mar; 7(2):222-30. PubMed ID: 24909984
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes.
    Freemark M; Bursey D
    Pediatrics; 2001 Apr; 107(4):E55. PubMed ID: 11335776
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The association between use of mealtime insulin pens versus vials and healthcare charges and resource utilization in patients with type 2 diabetes: a retrospective cohort study.
    Eby EL; Boye KS; Lage MJ
    J Med Econ; 2013 Oct; 16(10):1231-7. PubMed ID: 23834480
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of exenatide, pen insulin, and vial insulin on patient outcomes: a retrospective database analysis of persistence and first-year costs in a commercially insured population.
    Rashid N; McCombs JS; Schwartz E
    Clin Ther; 2012 May; 34(5):1145-58. PubMed ID: 22464691
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug usage patterns and treatment costs in newly-diagnosed type 2 diabetes mellitus cases, 2007 vs 2012: findings from a large US healthcare claims database analysis.
    Weng W; Liang Y; Kimball ES; Hobbs T; Kong S; Sakurada B; Bouchard J
    J Med Econ; 2016 Jul; 19(7):655-62. PubMed ID: 26855139
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Healthcare resource utilization and costs assessment of type 2 diabetes patients initiating exenatide BID or glargine: a retrospective database analysis.
    Pawaskar M; Zagar A; Sugihara T; Shi L
    J Med Econ; 2011; 14(1):16-27. PubMed ID: 21158486
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Direct costs associated with initiating NPH insulin versus glargine in patients with type 2 diabetes: a retrospective database analysis.
    Lee LJ; Yu AP; Johnson SJ; Birnbaum HG; Atanasov P; Buesching DP; Jackson JA; Davidson JA
    Diabetes Res Clin Pract; 2010 Jan; 87(1):108-16. PubMed ID: 19896233
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relation of body mass index in young adulthood and middle age to Medicare expenditures in older age.
    Daviglus ML; Liu K; Yan LL; Pirzada A; Manheim L; Manning W; Garside DB; Wang R; Dyer AR; Greenland P; Stamler J
    JAMA; 2004 Dec; 292(22):2743-9. PubMed ID: 15585734
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Roux-en-Y gastric bypass for nonobese patients with uncontrolled type 2 diabetes: a long-term evaluation.
    Ferraz ÁAB; de Sá VCT; Santa-Cruz F; Siqueira LT; Silva LB; Campos JM
    Surg Obes Relat Dis; 2019 May; 15(5):682-687. PubMed ID: 31005458
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
    Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
    Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
    [TBL] [Abstract][Full Text] [Related]  

  • 33. All-cause and diabetes-related healthcare costs among US adults with type 2 diabetes initiating exenatide once weekly or insulin glargine.
    Wittbrodt E; Kong AM; Moore-Schiltz L; Juneau P
    Diabetes Obes Metab; 2018 Mar; 20(3):672-680. PubMed ID: 29083520
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dosing of U-100 insulin and associated outcomes among Medicare enrollees with type 1 or type 2 diabetes.
    Eby EL; Van Brunt K; Brusko C; Curtis B; Lage MJ
    Clin Interv Aging; 2015; 10():991-1001. PubMed ID: 26124652
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased healthcare utilization costs following initiation of insulin treatment in type 2 diabetes: A long-term follow-up in clinical practice.
    Kalkan A; Bodegard J; Sundström J; Svennblad B; Östgren CJ; Nilsson PN; Johansson G; Ekman M
    Prim Care Diabetes; 2017 Apr; 11(2):184-192. PubMed ID: 27894781
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Not All Type-2-Diabetes Patients Increase Body Mass Index After Initiating Insulin: Results of Latent Class Analysis from the DPV Registry.
    Prinz N; Schwandt A; Borgert B; Hartmann B; Kempe HP; Mader JK; Merger S; Weber-Lauffer R; Wosch FJ; Holl RW
    Diabetes Technol Ther; 2021 Dec; 23(12):799-806. PubMed ID: 34524021
    [No Abstract]   [Full Text] [Related]  

  • 37. Healthcare resource utilization and related financial costs associated with glucose lowering with either exenatide or basal insulin: A retrospective cohort study.
    Holden SE; Morgan CL; Qiao Q; Jenkins-Jones S; Berni ER; Currie CJ
    Diabetes Obes Metab; 2017 Aug; 19(8):1097-1105. PubMed ID: 28218819
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Utilization patterns of insulin for patients with type 2 diabetes from national health insurance claims data in South Korea.
    Min KL; Koo H; Choi JJ; Kim DJ; Chang MJ; Han E
    PLoS One; 2019; 14(3):e0210159. PubMed ID: 30840630
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs.
    Bron M; Marynchenko M; Yang H; Yu AP; Wu EQ
    Postgrad Med; 2012 Jan; 124(1):124-32. PubMed ID: 22314122
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Direct medical costs of severe hypoglycaemic events in patients with type 2 diabetes in England: A retrospective database study.
    Holbrook T; Tang Y; Das R; Shankar RR; Tunceli K; Williams J; Radican L; Holden SE; Morgan CL; Piercy J; Currie CJ
    Int J Clin Pract; 2017 Jun; 71(6):. PubMed ID: 28544081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.